47.21 USD
+2.8 (+6.3%)
47.5 USD
+0.29 (+0.61%)
We assign a fundamental rating of 7 out of 10 to RIGL. RIGL was compared to 534 industry peers in the Biotechnology industry. While RIGL has a great health rating, its profitability is only average at the moment. RIGL is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make RIGL suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
RIGL had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of RIGL (46.72%) is better than 99.44% of its industry peers.
RIGL's Return On Equity of 96.34% is amongst the best of the industry. RIGL outperforms 99.44% of its industry peers.
With an excellent Return On Invested Capital value of 63.44%, RIGL belongs to the best of the industry, outperforming 99.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 40.17%, RIGL belongs to the top of the industry, outperforming 97.19% of the companies in the same industry.
RIGL's Operating Margin of 42.17% is amongst the best of the industry. RIGL outperforms 98.88% of its industry peers.
RIGL's Gross Margin of 93.10% is amongst the best of the industry. RIGL outperforms 93.07% of its industry peers.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, RIGL has more shares outstanding
The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.04, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.04, RIGL is doing good in the industry, outperforming 60.67% of the companies in the same industry.
The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of RIGL (0.88) is better than 93.63% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
RIGL's Debt to Equity ratio of 0.25 is on the low side compared to the rest of the industry. RIGL is outperformed by 67.42% of its industry peers.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | 0.04 |
ROIC/WACC7.21
WACC8.8%
2.3 Liquidity
A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
With a Current ratio value of 2.28, RIGL is not doing good in the industry: 72.10% of the companies in the same industry are doing better.
RIGL has a Quick Ratio of 2.14. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL's Quick ratio of 2.14 is on the low side compared to the rest of the industry. RIGL is outperformed by 71.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4307.14%, which is quite impressive.
The Revenue has grown by 79.13% in the past year. This is a very strong growth!
RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.77% yearly.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
The Earnings Per Share is expected to grow by 36.89% on average over the next years. This is a very strong growth
Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 15.70% on average per year.
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y36.89%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y15.7%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
RIGL is valuated cheaply with a Price/Earnings ratio of 7.65.
Based on the Price/Earnings ratio, RIGL is valued cheaply inside the industry as 97.57% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.37. RIGL is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 12.26, the valuation of RIGL can be described as correct.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaply inside the industry as 97.38% of the companies are valued more expensively.
RIGL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.20.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.65 | ||
| Fwd PE | 12.26 |
4.2 Price Multiples
98.69% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
97.38% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.58 | ||
| EV/EBITDA | 5.69 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
RIGL's earnings are expected to grow with 61.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y102.44%
EPS Next 3Y61.96%
5. Dividend
5.1 Amount
RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
47.21
+2.8 (+6.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.02%
Inst Owner Change8.15%
Ins Owners2.58%
Ins Owner Change0%
Market Cap856.86M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts76.67
Price Target43.69 (-7.46%)
Short Float %17.6%
Short Ratio4.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)11.74%
PT rev (3m)11.74%
EPS NQ rev (1m)42.6%
EPS NQ rev (3m)42.6%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)2.59%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.65 | ||
| Fwd PE | 12.26 | ||
| P/S | 3.04 | ||
| P/FCF | 12.58 | ||
| P/OCF | 12.57 | ||
| P/B | 7.29 | ||
| P/tB | 9.29 | ||
| EV/EBITDA | 5.69 |
EPS(TTM)6.17
EY13.07%
EPS(NY)3.85
Fwd EY8.16%
FCF(TTM)3.75
FCFY7.95%
OCF(TTM)3.76
OCFY7.96%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.02
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | 0.04 |
F-Score7
WACC8.8%
ROIC/WACC7.21
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y36.89%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year470.56%
EBIT Next 3Y88.04%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 503.1% in the next year.